Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > A possibility, the ANDA and 505(b)2 could BOTH be CBD
View:
Post by subaru1i on Apr 18, 2024 2:34pm

A possibility, the ANDA and 505(b)2 could BOTH be CBD

based, could both or just one (generic epidiolex) utilize SEDDS technology and be applied as two different drugs in two different areas of health care.   The logic for my thought is the single submission for CBD made by LABS to the FDA with regards to the DMF (drug master file). 

IF they are both CBD or even if 1 of them is, the good news for LABS shareholders is that it is NOT dependent on DEA rescheduling cannabis from 1 to 3.

If we look at the logic LABS followed (CEO of LABS being former CEO of Purdue Pharma Canada), and that logic being doing a CBD DMF to the FDA along with ANDA and 505(b)2,  imho, a strategy by the CEO of LABS that is not road blocked by the DEA what so ever. 

I think those that give this some thought may see as the 'path of least resistance' and can only be thankful our CEO is from the pharmaceutical industry to lead us.
Comment by okgonow on Apr 18, 2024 3:56pm
based, could both or just one (generic epidiolex) utilize SEDDS technology and be applied as two different drugs in two different areas of health care.   The logic for my thought is the single submission for CBD made by LABS to the FDA with regards to the DMF (drug master file).  IF they are both CBD or even if 1 of them is, the good news for LABS shareholders is that it is NOT ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities